B. Zegels

发表

Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture

J. Reginster, V. Rabenda, O. Bruyère, 2013, Rheumatology International.

Parathyroid hormone in the treatment of involutional osteoporosis: Back to the future

J. Reginster, B. Zegels, A. Taquet, 2010, Osteoporosis International.

A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis

C. Christiansen, J. Reginster, P. Ravn, 1997, Osteoporosis International.

A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.

J. Reginster, P. Franchimont, M. de Longueville, 1995, The American journal of medicine.

Long‐term (3 years) prevention of trabecular postmenopausal bone loss with low‐dose intermittent nasal salmon calcitonin

J. Reginster, P. Franchimont, M. de Longueville, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Risk of Hip Fracture in Community-dwelling and Institutionalized Osteoporotic Patients: A 3-year Study

M. Hiligsmann, J. Reginster, O. Bruyère, 2011 .

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.

J. Reginster, R. Eastell, R. Russell, 2001, Bone.

The Effect of Sodium Monofluorophosphate plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis

J. Reginster, H. Minne, L. Rovati, 1998, Annals of Internal Medicine.

Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX® criteria

M. Hiligsmann, O. Bruyère, J. Reginster, 2013, Rheumatology International.

Long-term performance in vitro and in vivo of dual-energy X-ray absorptiometry

J. Reginster, P. Franchimont, B. Zegels, 1995, Clinical Rheumatology.

New radioimmunoassay for determination of bone specific iso-enzymes of serum alkaline phosphatases activity (Ostase°): validation and clinical perspective

J. Reginster, P. Franchimont, J. Collette, 1993 .

Prevention of osteoporosis with nasal salmon calcitonin: Effect of anti-salmon calcitonin antibody formation

J. Reginster, P. Franchimont, B. Zegels, 1993, Osteoporosis International.

Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.

J. Reginster, O. Bruyère, A. Neuprez, 2008, Bone.

Influence of Daily Regimen Calcium and Vitamin D Supplementation on Parathyroid Hormone Secretion

J. Reginster, B. Zegels, N. Sarlet, 2001, Calcified Tissue International.

Prediction of Bone Loss Rate in Healthy Postmenopausal Women

J. Reginster, B. Zegels, J. Collette, 1997, Calcified Tissue International.

Acute biochemical variations induced by four different calcium salts in healthy male volunteers

J. Reginster, P. Franchimont, B. Zegels, 1993, Osteoporosis International.

Influence of daily calcium and vitamin D supplementation on parathyroid hormone secretion

J. Reginster, B. Zegels, A. Taquet, 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis.

J. Reginster, Y. Henrotin, P. Cloos, 2005, Osteoarthritis and cartilage.

Paget's disease of bone treated with a five day course of oral tiludronate.

P. Franchimont, J. Reginster, B. Zegels, 1993, Annals of the rheumatic diseases.

Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry

J. Reginster, J Y Reginster, T Chevallier, 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Ibandronate in the Management of Postmenopausal Osteoporosis

M. Hiligsmann, J. Reginster, V. Rabenda, 2009 .

Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: Normal range and fracture threshold for Western European (Belgian) postmenopausal females

J. Reginster, P. Franchimont, B. Zegels, 2005, Clinical Rheumatology.

Limited Clinical Utility of a Self-Evaluating Risk Assessment Scale for Postmenopausal Osteoporosis: Lack of Predictive Value of Lifestyle-Related Factors

S. Goemaere, K. Toye, W. Dewé, 1999, Calcified Tissue International.

O. Bruyère, P. Gillet, O. Ethgen, 2012, Archives of Orthopaedic and Trauma Surgery.

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study.

J. Reginster, O. Bruyère, D. Uebelhart, 2013, Osteoarthritis and cartilage.

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.

J. Reginster, O. Bruyère, Y. Henrotin, 2004, Bone.

Strontium ranelate: New data on fracture prevention and mechanisms of action

M. Hiligsmann, J. Reginster, O. Bruyère, 2009, Current osteoporosis reports.

Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study.

V. Rabenda, O. Bruyère, J. Reginster, 2012, Complementary therapies in medicine.

Evaluation of the simple calculated osteoporosis risk estimation (SCORE) in a sample of white women from Belgium.

J. Reginster, J. Devogelaer, S. Goemaere, 2001, Bone.

Subchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis.

O. Bruyère, Y. Henrotin, F. Richy, 2002, Bone.

Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis.

J. Reginster, O. Bruyère, F. Heraud, 2007, Mini reviews in medicinal chemistry.

Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC Index.

Olivier Ethgen, Jean-Yves Reginster, Eric Lejeune, 2003, The Journal of rheumatology.

Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study.

J. Reginster, V. Rabenda, O. Bruyère, 2012, Complementary therapies in medicine.